There are 3397 resources available
Q&A
Presenter: All Speakers
Session: ESMO Clinical Practice Guidelines 1
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: More intelligent trial design
Resources:
Slides
Webcast
744MO - AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)
Presenter: Jung-Yun Lee
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Conclusions and perspectives
Presenter: Roger Stupp
Session: Cutting edge diagnostics and innovation in the treatment of brain tumours
Resources:
Webcast
Invited Discussant LBA76 and LBA77
Presenter: Radka Obermannova
Session: Proffered Paper session 2 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast
Invited Discussant 2363MO, 2364MO and 2365MO
Presenter: Ursula Vogl
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Advanced pancreatic cancer case presentation
Presenter: Elene Mariamidze
Session: ESMO Clinical Practice Guidelines 1
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Mahesh Parmar
Session: More intelligent trial design
Resources:
Slides
Webcast
Advanced pancreatic cancer discussion
Presenter: Thierry Conroy
Session: ESMO Clinical Practice Guidelines 1
Resources:
Slides
Webcast
LBA104 - First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
Presenter: Antoni Vilaseca
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast